ClinicalTrials.gg

Program

olaparib

Also written as “Olaparib”, “AZD2281” and “KU-0059436 (AZD2281)(PARP inhibitor)”.

Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Prostatic Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 6 companies.

Furthest: phase 4, since Jun 10, 201576 company-led studies, 22 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca5915 open or runningphase 4since Jun 10, 2015Jun 27, 2007Apr 6, 2027phase 3 · NCT04421963
Merck125 open or runningphase 3since Mar 29, 2018Aug 3, 2016May 5, 2027phase 3 · NCT04380636
Novartis20 open or runningphase 3since Jan 25, 2021Jan 25, 2021none ahead
Boryung Pharmaceutical11 open or runningphase 1since Jul 7, 2025Jul 7, 2025none ahead
CSPC Pharmaceutical Group10 open or runningphase 1since Apr 7, 2024Apr 7, 2024none ahead
Daewoong Pharmaceutical11 open or runningphase 1since Jan 19, 2026Jan 19, 2026Mar 2027phase 1 · NCT07371104

Also a collaborator on its studies: myriad-genetic-laboratories-inc, frontier-science-technology-research-foundation-inc, Hoffmann-La Roche, myriad-genetics-inc, iqvia-pty-ltd, covance, theradex, parexel and kudos-pharmaceuticals-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jan 7, 2009.

  1. Mar 30, 2020Phase 4 study in Ovarian NeoplasmsAstraZeneca · NCT04330040 · 202 enrolled · India
  2. May 5, 2020Phase 3 study in Lung NeoplasmsMerck · NCT04380636 · 870 enrolled · United States, Argentina, Canada and more
  3. May 19, 2020Phase 3 study in Ovarian NeoplasmsAstraZeneca · NCT04421963 · 185 enrolled · United States, Belgium, Bulgaria and more
  4. Jul 1, 2020Phase 3 study in Colorectal NeoplasmsMerck · NCT04456699 · 335 enrolled · United States, Australia, Belgium and more
  5. Nov 5, 2020Phase 3 study in Small Cell Lung CarcinomaMerck · NCT04624204 · 672 enrolled · United States, Australia, Belgium and more
  6. Jan 25, 2021Novartis's first study: phase 3 study in Ovarian NeoplasmsNew to NovartisNovartis · NCT04729387 · 358 enrolled · United States, Argentina, Australia and more
  7. Apr 20, 2021Phase 3 study in Ovarian NeoplasmsAstraZeneca · NCT04884360 · 366 enrolled · Chile, China, Colombia and more
  8. Dec 20, 2021Phase 3 study in Metastatic Castration-resistant Prostate CancerAstraZeneca · NCT05171816 · 110 enrolled · China
  9. Feb 17, 2022Phase 1 study in Ovarian NeoplasmsNovartis · NCT05258747 · 70 enrolled · India
  10. Jul 5, 2022Phase 2 study in Breast NeoplasmsAstraZeneca · NCT05498155 · 50 enrolled · United States, Australia, Austria and more
  11. Jul 11, 2022Phase 4 study in Metastatic Castration-resistant Prostate CancerAstraZeneca · NCT05457257 · 43 enrolled · China
  12. Apr 7, 2024CSPC Pharmaceutical Group's first study: phase 1 study in Healthy ParticipantsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06360445 · 102 enrolled · China
  13. Jul 7, 2025Boryung Pharmaceutical's first study: phase 1 study in Ovarian NeoplasmsNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT07069335 · 24 planned · South Korea
  14. Jan 19, 2026Daewoong Pharmaceutical's first study: phase 1 study in NeoplasmsNew to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT07371104 · 40 planned · South Korea

Ahead

  1. Mar 2027Primary completion: phase 1 study in NeoplasmsDaewoong Pharmaceutical · NCT07371104
  2. Apr 6, 2027Primary completion: phase 3 study in Ovarian NeoplasmsAstraZeneca · NCT04421963
  3. May 5, 2027Primary completion: phase 3 study in Lung NeoplasmsMerck · NCT04380636
  4. Oct 22, 2027Primary completion: phase 2 study in Metastatic Castration-Resistant Prostate CancerMerck · NCT02861573

TargetBeta

“PARP 1, 2 and 3 inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 76 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07371104Neoplasms · South Korea1RecruitingDaewoong PharmaceuticalMar 202740
NCT07069335Ovarian Neoplasms · South Korea1RecruitingBoryung PharmaceuticalMay 15, 202624
NCT06360445Healthy Participants · China1CompletedCSPC Pharmaceutical GroupAug 21, 2022102
NCT05457257Metastatic Castration-resistant Prostate Cancer · China4Active, not recruitingAstraZenecaOct 22, 202443
NCT05498155Breast Neoplasms · United States, Australia, Austria and more2CompletedAstraZenecaNov 20, 202450
NCT05258747Ovarian Neoplasms · India1CompletedNovartisOct 20, 202270
NCT05171816Metastatic Castration-resistant Prostate Cancer · China3Active, not recruitingAstraZenecaJan 22, 2024110
NCT04884360Ovarian Neoplasms · Chile, China, Colombia and more3Active, not recruitingAstraZenecaJul 27, 2026366
NCT04729387Ovarian Neoplasms · United States, Argentina, Australia and more3TerminatedNovartisApr 21, 2023358
NCT04624204Small Cell Lung Carcinoma · United States, Australia, Belgium and more3Active, not recruitingMerckOct 28, 2027672
NCT04456699Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedMerckMar 27, 2023335
NCT04421963Ovarian Neoplasms · United States, Belgium, Bulgaria and more3Active, not recruitingAstraZenecaApr 6, 2027185
NCT04380636Lung Neoplasms · United States, Argentina, Canada and more3Active, not recruitingMerckMay 5, 2027870
NCT04330040Ovarian Neoplasms · India4CompletedAstraZenecaSep 30, 2022202
NCT04269200Endometrial Neoplasms · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaJul 8, 2024805
NCT04239014Ovarian Neoplasms · United States, Canada, Italy and more2WithdrawnAstraZenecaJan 25, 20210
NCT04191135Triple Negative Breast Neoplasms · United States, Canada, Chile and more2TerminatedMerckDec 15, 2022462
NCT04236414Neoplasms · Denmark, France, Germany and more1CompletedAstraZenecaFeb 4, 202516
NCT04123366Solid Tumors · United States, Argentina, Australia and more2CompletedMerckJun 8, 2026333
NCT03976362Carcinoma · United States, Argentina, Australia and more3CompletedMerckSep 21, 2023851
NCT03976323Carcinoma · United States, Argentina, Australia and more3CompletedMerckFeb 7, 20241,003
NCT03834519Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedMerckMar 14, 2022793
NCT03775486Non-small Cell Lung Cancer NSCLC · United States, Belgium, Hungary and more2Active, not recruitingAstraZenecaJan 11, 2021401
NCT03742895Advanced Solid Neoplasms · United States, Argentina, Australia and more2Active, not recruitingMerckAug 12, 2025329
NCT03740165Ovarian Neoplasms · United States, Australia, Belgium and more3CompletedMerckAug 26, 20241,367
NCT03737643Ovarian Neoplasms · United States, Austria, Belgium and more3Active, not recruitingAstraZenecaMar 17, 20251,407
NCT03732820Metastatic Castration-resistant Prostate Cancer · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaJul 30, 2021895
NCT03553108Malignant Solid Tumor · Belgium1CompletedAstraZenecaMar 12, 201918
NCT03486873Hematologic Neoplasms · United States, Argentina, Australia and more3RecruitingMerckAug 4, 20433,500
NCT03534453Ovarian Neoplasms · China, Malaysia3CompletedAstraZenecaJan 27, 2025225
NCT03459846Urinary Bladder Neoplasms · United States, Canada, Russia and more2Active, not recruitingAstraZenecaOct 15, 2020154
NCT03402841Ovarian Neoplasms · Austria, Belgium, Bulgaria and more3CompletedAstraZenecaOct 2, 2020279
NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more2Active, not recruitingAstraZenecaSep 13, 2024528
NCT03286842HER2-ve Metastatic Breast Cancer · United States, Bulgaria, Canada and more3CompletedAstraZenecaOct 8, 2021256
NCT03106987Carcinoma, Ovarian Epithelial · Belgium, Canada, Denmark and more3CompletedAstraZenecaFeb 15, 2021220
NCT03022409Squamous Cell Carcinoma of Head and Neck · United States, France, Taiwan1CompletedAstraZenecaJan 20, 202121
NCT02987543Metastatic Castration-resistant Prostate Cancer · United States, Argentina, Australia and more3CompletedAstraZenecaJun 4, 2019387
NCT02983799Ovarian Neoplasms · United States, Canada2CompletedAstraZenecaDec 3, 2020272
NCT02861573Metastatic Castration-Resistant Prostate Cancer2Active, not recruitingMerckOct 22, 20271,200
NCT02561832Breast Neoplasms · United States, Spain1TerminatedAstraZenecaSep 30, 201615
NCT02476968BRCA or HRR+ Mutated Ovarian Cancer Patients · Bulgaria, Canada, Czechia and more4CompletedAstraZenecaApr 17, 2020181
NCT02430311Advanced Solid Tumours · China1CompletedAstraZenecaJul 27, 201636
NCT02392676Ovarian Neoplasms · United States, Korea, Republic of, Peru and more3WithdrawnAstraZenecaJun 20190
NCT02282020Ovarian Neoplasms · United States, Argentina, Belgium and more3CompletedAstraZenecaOct 10, 2018266
NCT02184195Pancreatic Neoplasms · United States, Australia, Belgium and more3CompletedAstraZenecaJan 15, 2019154
NCT02093351Neoplasms · Belgium, Denmark, France and more1CompletedAstraZenecaApr 30, 201579
NCT02032823Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaMar 27, 20201,837
NCT02000622Breast Neoplasms · United States, Bulgaria, China and more3CompletedAstraZenecaDec 9, 2016302
NCT01972217Prostatic Neoplasms · United States, Belgium, Canada and more2CompletedAstraZenecaSep 22, 2017158
NCT01924533Stomach Neoplasms · China, Japan, Korea, Republic of and more3CompletedAstraZenecaApr 4, 2016525
NCT01921140Neoplasms · Belgium, Denmark, Netherlands and more1CompletedAstraZenecaApr 8, 201460
NCT01874353Ovarian Neoplasms · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaSep 19, 2016327
NCT01851265Neoplasms · Belgium, Netherlands, United Kingdom1CompletedAstraZenecaOct 18, 201332
NCT01844986Pathologic Complete Response · United States, Australia, Brazil and more3Active, not recruitingAstraZenecaMay 17, 2018450
NCT01813474Neoplasms · Japan1CompletedAstraZenecaAug 31, 201623
NCT01078662Ovarian · United States, Australia, Germany and more2CompletedAstraZenecaJul 31, 2012298
NCT01081951Ovarian Neoplasms · United States, Australia, Belgium and more2Active, not recruitingAstraZenecaOct 10, 2011162
NCT01063517Stomach Neoplasms · Korea, Republic of2CompletedAstraZenecaMay 11, 2012124
NCT00912743Colorectal Neoplasms · United States2CompletedAstraZenecaMar 201233
NCT00819221Solid Tumors · Italy, Switzerland1TerminatedAstraZenecaNov 30, 201144

How it is read

Names in the registry

  • “Olaparib”, 38 entries
  • “olaparib”, 10 entries
  • “AZD2281”, 10 entries
  • “KU-0059436 (AZD2281)(PARP inhibitor)”, 10 entries
  • “Olaparib 300mg tablets”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.